ERBB2 and breast cancer: If this survival difference is not due to the initial tumor response to NAC, we can hypothesize that the difference may be due to a more intrinsic aggressiveness of HER2 score 1 + BC, with a stronger tendency to micro metastasize or develop a resistance to treatment, however this requires specific confirmatory studies.